How to buy Instil Bio stock

Instil Bio, Inc is a biotechnology business based in the US. Instil Bio shares (TIL) are listed on the NASDAQ and all prices are listed in US Dollars. Instil Bio employs 242 staff and has a trailing 12-month revenue of around 0.00.

Instil Bio stock price (NASDAQ: TIL)

Use our graph to track the performance of TIL stocks over time.

Instil Bio shares at a glance

• Key figures

Information last updated 2021-07-23.

52-week range	$14.42 - $29.49
50-day moving average	$18.33
200-day moving average	$19.44
Wall St. target price	$28.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Instil Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Instil Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Instil Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Instil Bio financials

Revenue TTM	$94,000
Gross profit TTM	$138,000
Return on assets TTM	-12.11%
Return on equity TTM	-25.12%
Profit margin	0%
Book value	$5.17
Market capitalisation	$2.5 billion

TTM: trailing 12 months

Shorting Instil Bio shares

There are currently 3.6 million Instil Bio shares held short by investors – that's known as Instil Bio's "short interest". This figure is 5.8% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting Instil Bio shares can be evaluated.

Instil Bio's "short interest ratio" (SIR)

Instil Bio's "short interest ratio" (SIR) is the quantity of Instil Bio shares currently shorted divided by the average quantity of Instil Bio shares traded daily (recently around 398500.44692737). Instil Bio's SIR currently stands at 8.95. In other words for every 100,000 Instil Bio shares traded daily on the market, roughly 8950 shares are currently held short.

To gain some more context, you can compare Instil Bio's short interest ratio against those of similar companies.

• Gilead Sciences (GILD.US): 4.3
• Vertex Pharmaceuticals Incorporated (VRTX.US): 1.6
• Amgen (AMGN.US): 4.42

However Instil Bio's short interest can also be evaluated against the total number of Instil Bio shares, or, against the total number of tradable Instil Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Instil Bio's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Instil Bio shares in existence, roughly 30 shares are currently held short) or 0.0661% of the tradable shares (for every 100,000 tradable Instil Bio shares, roughly 66 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Instil Bio.

Find out more about how you can short Instil Bio stock.

Instil Bio share dividends

We're not expecting Instil Bio to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.93% forward annual dividend yield)
• Amgen (AMGN.US) (2.69% forward annual dividend yield)

Instil Bio overview

Instil Bio, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas. .

Frequently asked questions

What percentage of Instil Bio is owned by insiders or institutions?
Currently 13.499% of Instil Bio shares are held by insiders and 51.037% by institutions. How many people work for Instil Bio?
Latest data suggests 242 work at Instil Bio. When does the fiscal year end for Instil Bio?
Instil Bio's fiscal year ends in December. Where is Instil Bio based?
Instil Bio's address is: 3963 Maple Avenue, Dallas, TX, United States, 75219